Patrick Hwu, President and CEO at Moffitt Cancer Center, shared a post on LinkedIn:
“Congrats to Keiran Smalley and team on their new Journal for ImmunoTherapy of Cancer paper!
A 3-drug immunotherapy combo may overcome resistance in melanoma, restoring immune response and shrinking tumors in preclinical models without added side effects.
Title: Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models
Authors: Manali S Phadke, Jiannong Li, Sathya Sriramareddy, Paulo C Rodriguez, Brian Ruffell, Vincent C Luca, Thuy T T Tran, Yian Ann Chen, Keiran S M Smalley
More posts featuring Patrick Hwu on OncoDaily.